{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":18},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06497556\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"Krascendo 1","nct_id":"NCT06497556","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krascendo-1-nct06497556. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"Krascendo 1","arms":[{"description":"Participants will receive divarasib orally, once daily (QD).","label":"Divarasib","type":"EXPERIMENTAL"},{"description":"Participants will receive sotorasib orally QD or adagrasib orally twice a day (BID)","label":"KRAS G12C inhibitor","type":"ACTIVE_COMPARATOR"}],"collaborators":["Chugai Pharmaceutical"],"completion_date":{"date":"2029-11-30","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer","KRAS G12C Lung Cancer"],"enrollment":{"count":338,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Divarasib","type":"DRUG"},{"name":"Sotorasib","type":"DRUG"},{"name":"Adagrasib","type":"DRUG"}],"last_update":"2026-09-16","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-05-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 4 years"}],"references":[],"start_date":{"date":"2024-09-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06497556"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krascendo-1-nct06497556"}